Navigation Links
MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations

    MDS Pharma Services to Focus on the Delivery of Early Stage Services -
    Discovery Through Phase IIa

TORONTO, July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Phase II-IV operations to INC Research,(R) Inc.

Under the terms of the agreement, INC Research, a leading global provider of contract research organization services headquartered in Raleigh, North Carolina, has acquired MDS Pharma Services Phase II-IV operations, which includes approximately 800 employees who conduct large, multi-site clinical trials in more than 25 countries.

"The completion of this transaction supports our efforts to advance MDS Pharma Services' top-three leadership position in the delivery of Early Stage services," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc.

MDS expects to provide additional detail with respect to the divestiture of its Phase II-IV operations when the Company reports financial results for its fiscal third quarter (three months ending July 31, 2009).

The Company's decision to sell its MDS Pharma Services Late Stage operations, which are comprised of Phase II-IV operations and Central Labs, are a result of MDS's ongoing strategic review process.

A suitable buyer is being sought for Central Labs, which conducts analysis of clinical-trial samples to monitor safety and to test for physiological impact. Central Labs has more than 600 employees at six sites in Europe, North America and Asia.

MDS Pharma Services' New Strategic Focus

Additional background materials pertaining to the new strategic focus for MDS Pharma Services can be found on MDS Inc.'s Website at

About INC Research,(R) Inc.

INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process(R) methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis Completes $15 Million Equity Financing From New and Existing Investors
2. CEL-SCI Completes $5.85 Million Registered Direct Offering
3. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
4. BioMed Realty Trust Completes $350 Million Financing for Center for Life Science Boston
5. Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology
6. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
7. NeuroTherm Completes Acquisition of the Micron Epidural Catheter
8. Homefront Diabetic Services Completes Accreditation with ACHC
9. STAAR Surgical Completes Common Stock Offering
10. SETO Holdings, Inc. Completes Agreement to Acquire Advanced Hearing Centers, Inc. and Has Disposed of All Existing Business; New Management has been installed
11. Inspire Medical Systems Completes $17 Million Series B Financing
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists that ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... at . The directory is specialized and only includes chiropractic clinics ... to find a competent and trustworthy alternative health practitioner when back pain sets ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... experience this summer, ushering in a new era of publicly accessible automated technology. ... shuttle, will continue to offer guests an up-close look at the shuttle at ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... and fun atmosphere for Halloween festivities, the Word of Life Christian Church of ... board game, and featuring a giant 1.25 ton pile of candy dubbed “Candy ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... community across the United States to access life-saving information provided directly ... Mesothelioma will consist of three individual conferences in three major cities: Houston, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Nevro Corp. (NYSE: NVRO ), ... solutions for the treatment of chronic pain, today announced that ... Patent and Trademark Office (USPTO) has denied instituting an ... (the ,102 patent).  --> ... Scientific Corporation filed two petitions challenging the validity of certain ...
(Date:11/30/2015)... SAN FRANCISCO , Nov. 30, 2015 ... and Designers of Things (DoT ) co-located events ... Printing and the Internet of Things, will draw more ... San Jose Convention Center. The events, combined ... their latest technologies. --> ...
(Date:11/30/2015)... and BOCA RATON, Fla. ... for the Commercialization of Public Research (the Institute) ... with KynderMed , a medical device start-up company ... supports new company creation based on publicly-funded research, and ... Florida -based universities and research institutions. ...
Breaking Medicine Technology: